臨床婦人科産科61巻10号

2007年10月発行

今月の臨床 ここまできた分子標的治療

分子標的治療の臨床応用

5．大腸癌

著者： 山本浩文¹ 関本貢嗣¹ 門田守人¹

所属機関： ¹大阪大学大学院外科学講座・消化器外科

ページ範囲：P.1276 - P.1281

文献概要

はじめに
　現在大腸癌の治療に利用される化学療法剤としては，5-FU，l-LV，CPT-11（irinotecan），L-OHP（oxaliplatin）の4剤が主であり，通常l-LVは5-FUのbiological modulatorとしてセットで使用される（表1）．多くの臨床試験の結果から，5-FU／LVはCPT-11やL-OHPと組み合わせて多剤併用療法（FOLFOX，FOLFIRI，IFL）として利用されるようになった（表1）．大腸癌に対する分子標的治療薬としてすでに臨床効果の認められているものは，抗EGFR（epidermal growth factor receptor）抗体と抗VEGF（vascular endothelial growth factor）抗体の2つが代表的であるが，これらの分子標的治療薬も多くの臨床試験の結果，従来の多剤併用療法との組み合わせで臨床の場に登場した．本稿ではこれら2つの分子標的薬について臨床試験の結果を中心に紹介する．

参考文献

1）Fracasso PM, Burris H, Arquette MA, et al : A phase 1 escalating single─dose and weekly fixed─dose study of cetuximab : pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 13 : 986─993, 2007

2）Baselga J, Pfister D, Cooper MR, et al : Phase I studies of anti─epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18 : 904─914, 2000

3）Saltz LB, Meropol NJ, Loehrer PJ, et al : Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 : 1201─1208, 2004

4）Cunningham D, Humblet Y, Siena S, et al : Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan─refractory metastatic colorectal cancer. N Engl J Med 22 : 337─345, 2004

5）Lenz HJ, Van Cutsem E, Khambata─Ford S, et al : Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24 : 4914─4921, 2006

6）Tabernero JM, Van Cutsem E, Sastre J et al : An international phaseIIstudy of cetuximab in combination with oxaliplatin／5FU／FA（FOLFOX4）in the first─line treatment of patients with metastatic colorectal cancer expressing EGFR : preliminary results. The Annual Meeting of American Society of Clinical Oncology, Abstract＃3512, 2004

7）Van Cutsem EJD, Tabernero J, Diaz─Rubio E, et al : An international phaseII study of cetuximab in combination with FOLFOX4 in the first─line treatment of patients with metastatic colorectal cancer expressing EGFR. Ann Oncol 15（suppl 3） : 91, Abstract＃339, 2004

8）Bokemeyer C, Bondarenko I, Makhson A, et al : Cetuximab plus 5─FU／FA／oxaliplatin（FOLFOX─4）versus FOLFOX─4 in the first─line treatment of metastatic colorectal cancer（mCRC）: OPUS, a randomized phase II study. The Annual Meeting of American Society of Clinical Oncology, Abstract＃4035, 2007

9）Saltz LB, Lentz HJ, Hochster S et al : Randomized phase II trials of cetuximab／bevacizumab／irinotecan（CBI）versus cetuximab／bavacizumab（CB）in irinotecan─refrectory colorectal cancer. The Annual Meeting of American Society of Clinical Oncology, Abstract＃508, 2005

10）Chung KY, Shia J, Kemeny NE, et al : Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23 : 1803─1810, 2005

11）Lenz HJ, Van Cutsem E, Khambata─Ford S, et al : Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24 : 4914─4921, 2006

12）Saltz L, Kies M, Abbruzzesse JL, et al : The presence and intensity of the cetuximab─induced acne─like rash predicts increased survival in studies across multiple malignancies. The Annual Meeting of American Society of Clinical Oncology, Abstract＃817, 2003

13）Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al : Phase II, randomized trial comparing bevacizumab plus fluorouracil（FU）／leucovorin（LV）with FU／LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 : 60─65, 2003

14）Hurwitz H, Fehrenbacher L, Novotny W, et al : Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 : 2335─2342, 2004

15）Hochster H, Welles L, Hart L, et al : Bevacizumab（B）with oxaliplatin（O）─based chemotherapy in the first─line therapy of metastatic colorectal cancer（mCRC）: preliminary results of the randomized “TREE─2” trial. The American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Abstract＃241, 2005

16）Giantonio BJ, Catalano PJ, Meropol NJ, et al : Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin（FOLFOX4）for previously treated metastatic colorectal cancer : Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25 : 1539─1544, 2007